Pipeline

PharmAbcine has focused on the development of novel antibody therapeutics since the company’s foundation in 2008 and laid the groundwork for the commercialization of olinvacimab, PMC-309, PMC-403, and PMC-402.


We will also become an innovative global biotech company through the development of other new candidates such as PMC-005BL, PMC-122, PMC-401, and PMC-401s



Core Pipeline

 

 Olinvacimab (TTAC-0001)


   Angiogenesis Inhibitor

   VEGFR2

   Clinical

   mAb



New Candidates

  

  PMC-005BL


   New Candidates

   EGFRvIII

   Preclinical/Optimization

   ADC/CAR-T/RIT



  

  PMC-901


   New Candidates

   VEGF-A

   Preclinical

   Biosimilar


  

  PMC-309


   Immune checkpoint inhibitor

   VISTA

   Preclinical

   mAb



신생후보물질

  

  PMC-122


   New Candidates

   PD-L1xCD47

   Preclinical/Optimization

   Bispecific Ab



  

  PMC-902


   New Candidates

   VEGF/PIGF

   Preclinical

   Biosimilar


  

  PMC-402


   Immune Activator

   TIE2

   Preclinical 

   mAb



신생후보물질

  

  PMC-401

   

   New Candidates

   ANG2

   Preclinical

   mAb



  

  Core Technology


   Fully Human Antibody Library

   Antibody Development

   Antibody Engineering 

   > More


  

  PMC-403


   Vessel-normalizer

   TIE2

   Preclinical 

   mAb



신생후보물질

  

  PMC-401s


   New Candidates

   ANG2

   Preclinical/Optimization

   mAb




LinkedIn  I   Facebook  I  YouTube



    • 2F, Research Building 2, 70, Yuseong-daero 1689 beon-gil,
      Yuseong-gu, Daejeon, 34047, Republic of Korea
    • HQ +82-42-863-2017
    • R&D Center +82-42-861-2017
    • FAX +82-42-863-2080
  • COPYRIGHT BY PharmAbcine Inc. ALL RIGHTS RESERVED.